the Immunohistochemical Study of Stathmin-1 as A Prognostic factor In Non-small cell lung carcinoma

Authors

  • Nadhema Bahaa Hussein Wetwet Specialist in Clinical Pathology
  • Hadeel Abdulelah Karbel KERBEL Professor of Clinical Pathology, Medical College of Hammurabi- University of Babylon.
  • Ali Salih Baay Baay Professor of Respiratory Medicine, Medical College of Hammurabi- University of Babylon.
  • Muhammed Whaeeb Salman Al-Obaidy Department of Medicine, College of Medicine – University of Baghdad https://orcid.org/0000-0001-8808-4082

DOI:

https://doi.org/10.32007/jfacmedbagdad.6441948

Keywords:

Stathmin-1, Lung Cancer.

Abstract

Background

Stathmin1 (also known as metablastin) is a major microtubule-depolymerizing protein that involved in cell cycle progression and cell motility.

 Stathmin1 has been found to be up-regulated in some cancers and correlated with cell differentiation and proliferation.  

Stathmin1 is a major cytosolic phosphoprotein that regulates microtubule dynamics and is associated with malignant phenotypes in various cancers, including non-small cell lung cancer.

 

Objective

 To evaluate the role of Immunohistochemical expression of stathmin1 in non-small lung carcinoma and its correlation to different prognostic factors or parameters.

 

Materials and methods

This retrospective study carried on formalin fixed paraffin embedded surgical specimens of lung tumors  Applying the Immunohistochemical techniques by using the primary antibodies to stathmin1, statistical analysis done and assessment of correlation with different clinical and pathological parameters measured.

 

 Results

Fifty cases of Non-small lung carcinomas that 42% adenocarcinoma,44% squamous cell carcinoma 10% adenosequamous and 4% non-small lung carcinoma 84 % were Stathmin-1 positive.

 No significant correlation between Stathmin-1 expression with age and gender of patients but Stathmin-1 expression were correlated with parameters including type and grade of tumor.

High expression was noted in poorly differentiated tumors.

 

Conclusions

Measurement of stathmin1 level may be a beneficial prognostic biomarker for non-small lung tumors especially those of poorly differentiated tumors

Stathmin1 expression in non-small cell lung carcinoma significantly correlated with poor tumor differentiation and could be considered as independent prognostic factor.

Downloads

Download data is not yet available.

References

Ferlay j, Soerjomataram I,Ervic M,Dikshit R,Eser S,

MathersC et al. Globocan2012v1.0,Cancer Incidence

and Mortality Worldwide:IARC CancerBase No.11.

Yoshizawa A, Motoi N, Riely GJ, et al. Impact of

proposed IASLC/ATS/ERS classification of lung

adenocarcinoma: prognostic subgroups and

implications for further revision of staging based on

analysis of 514 stage I cases. Mod Pathol.

;24(5):653-664.

Iancu-Rubin C, Nasrallah CA, Atweh GF. Stathmin

prevents the transition from a normal to an endomitotic

cell cycle during megakaryocytic differentiation. Cell

Cycle (Georgetown, Tex) 2005;4(12):1774-82.

Alli E, Yang JM, Hait WN. Silencing of stathmin

induces tumor-suppressor function in breast cancer cell

lines harboring mutant p53. Oncogene

;26(7):1003-12 17.

Mistry SJ, Benham CJ, Atweh GF. Development of

ribozymes that target stathmin, a major regulator of the

mitotic spindle. Antisense Nucleic Acid Drug Dev

;11(1):41-9 .

Yuan RH, Jeng YM, Chen HL, et al. Stathmin

overexpression cooperates with p53 mutation and

osteopontin overexpression, and is associated with

tumour progression, early recurrence, and poor

prognosis in hepatocellular carcinoma. J Pathol 2006;

:549–558.

Biaoxue R, Liu Hua, Fu Tian, Gao Wenlong,

Increased stathmin in serum as a potential tumor

marker for lung adenocarcinoma. Japanese Journal of

Clinical Oncology, Volume 47, Issue 4, April 2017,

–349.

Immunohistochemical Study of Stathmin-1 as A Prognostic factor In Nadhema B. Hussein

Non-small cell lung carcinoma.

J Fac Med Baghdad 202 Vol.64 No. 4, 2022

Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D,

Higo M, et al. Overexpression of stathmin in oral

squamous-cell carcinoma: correlation with tumour

progression and poor prognosis. Br J Cancer. 2006;94:

-23.

Belletti B, Baldassarre G. Stathmin: a protein with

many tasks. New biomarker and potential target in

cancer. Expert Opin Ther Targets. 2011; 15:1249-66.

Yurong L, Rong Biaoxue, Li Wei et al. Stathmin

overexpression is associated with growth, invasion and

metastasis of lung adenocarcinoma: Oncotarget. 2017;

:16 ,26000-26012.

Biaoxue R, Increased stathmin in serum as a

potential tumor marker for lung adenocarcinoma.

Japanese Journal of Clinical Oncology. 2017; 7: 47

-668.

Shimizu K. Prognostic impact of stathmin 1

expression in patients with lung adenocarcinoma. The

Journal of Thoracic and Cardiovascular Surgery.

:4,154, 1406-1417.

Downloads

Published

2023-01-13

How to Cite

1.
Wetwet NBH, KERBEL HAK, Baay ASB, Al-Obaidy MWS. the Immunohistochemical Study of Stathmin-1 as A Prognostic factor In Non-small cell lung carcinoma. JFacMedBagdad [Internet]. 2023 Jan. 13 [cited 2023 Jan. 30];64(4):199-202. Available from: https://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/1948